SEARCH

SEARCH BY CITATION

References

  • 1
    Pruthi RK. A practical approach to genetic testing for von Willebrand disease. Mayo Clin Proc 2006; 81: 67991.
  • 2
    Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 4549.
  • 3
    Budde U. Diagnosis of von Willebrand disease subtypes: implications for treatment. Haemophilia 2008; 14(Suppl. 5): 2738.
  • 4
    Rodeghiero F. von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8: 292300.
  • 5
    National Institutes of Health Staff, NIH-NHLBI. Clinical guidelines: the diagnosis, evaluation and management of von Willebrand disease. http://www.nhlbi.nih.gov/guidelines/vwd/1_frontmatter.htm . 2007. U.S. Department of Health and Human Services.
  • 6
    Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98: 34658.
  • 7
    Turecek PL, Siekmann J, Schwarz HP. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor. Semin Thromb Hemost 2002; 28: 14060.
  • 8
    Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S1721.
  • 9
    Howard MA, Firkin BG. Ristocetin – a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 3629.
  • 10
    Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 3068.
  • 11
    Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost 2006; 12: 617.
  • 12
    Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, Owen WG. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008; 6: 32330.
  • 13
    Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15: 50511.
  • 14
    Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88: 569.
  • 15
    Redaelli R, Corno AR, Borroni L, Mostarda G, Nichelatti M, Morra E, Baudo F. Von Willebrand factor ristocetin cofactor (VWF:RCo) assay: implementation on an automated coagulometer (ACL). J Thromb Haemost 2005; 3: 26848.
  • 16
    European Pharmacopoeia. Assay of Human von Willebrand Factor. Monograph 2.7.21. 2009.
  • 17
    Von Neumann J, Kent RH, Bellinson HB, Hart BI. The mean square successive difference. Ann Math Stat 1941; 12: 15362.
  • 18
    Zuzel M, Nilsson IM, Aberg M. A method for measuring plasma ristocetin cofactor activity. Normal distribution and stability during storage. Thromb Res 1978; 12: 74554.
  • 19
    Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991; 266: 814955.
  • 20
    Schwarz HP, Ewenstein B, Turecek PL. The 1st International Standard for von Willebrand Factor concentrate: more to come? Thromb Haemost 2002; 88: 3767.
  • 21
    Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 26470.
  • 22
    Nurden P, Nurden AT, La Marca S, Punzo M, Baronciani L, Federici AB. Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene. Haematologica 2009; 94: 16279.